Glioblastoma: State of the Art and Future Perspectives

Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, r...

Full description

Saved in:
Bibliographic Details
Other Authors: Tabatabai, Ghazaleh (Editor), Wakimoto, Hiroaki (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_68811
005 20210501
003 oapen
006 m o d
007 cr|mn|---annan
008 20210501s2020 xx |||||o ||| 0|eng d
020 |a books978-3-03928-261-6 
020 |a 9783039282609 
020 |a 9783039282616 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-03928-261-6  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a GP  |2 bicssc 
072 7 |a PS  |2 bicssc 
100 1 |a Tabatabai, Ghazaleh  |4 edt 
700 1 |a Wakimoto, Hiroaki  |4 edt 
700 1 |a Tabatabai, Ghazaleh  |4 oth 
700 1 |a Wakimoto, Hiroaki  |4 oth 
245 1 0 |a Glioblastoma: State of the Art and Future Perspectives 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (784 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad "one-for-all" treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/2577  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/68811  |7 0  |z DOAB: description of the publication